Taiwan Liposome Company EBIT

Taiwan Liposome Company posts a EBIT of $-810M as of June 2021. That compares with $-920M in the prior-year period — up 11.5% year over year. That is below the Healthcare sector average of $23B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Taiwan Liposome Company's EBIT was $-920M. The latest reading is $-810M — a 11.5% year-over-year increase (period ending June 2021). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a EBIT near $23B is typical. Taiwan Liposome Company's $-810M is lower that level. That is roughly 103.5% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Taiwan Liposome Company's financial statement story. At $-810M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for TLC's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $23B), and (3) consistency with growth and profitability. This page covers the first two; Taiwan Liposome Company's other metric pages and overview cover the third.